



Stock Symbol-	WKBT.OB
Market Cap-	\$ 93,881,700
Recent Price-	\$3.35
Intermediate Target Price	\$6.05
52 week trading range:	\$1.77-6.99
Shares Outstanding:	28,024,388

CORPORATE INFORMATION

PHONE 1-310-819-2948  
WEB: [www.weikangbio.com](http://www.weikangbio.com)

## WEIKANG BIO-TECHNOLOGY GROUP Co., Inc.

Weikang Bio-Technology Group Company, Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM) and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit [www.weikangbio.com](http://www.weikangbio.com).

News Flash: on October 4, 2010, the Company announced they intend to launch three new therapeutics during the first quarter of 2011, expecting its new products to have the potential of approximately \$3.1 million in revenue and up to the potential of \$1.1 million in net income combined in 2011.

Last month the Company announced it had launched its new program called *Rongrun Good Health Package*. Dr. Ying Wang, Chairman and CEO of Weikang Bio-Technology Group Co. Inc. stated, “This is our first bundled product which we believe offers consumers enhanced value and will accelerate the market acceptance of our new products. We intend to continue expanding our market share through regularly launching proprietary, high quality, and high margin, new products that enhance consumers’ health and overall wellbeing. We are also supporting our new products by continually building brand recognition through aggressive marketing campaigns and sales incentives.”

This new program alone is expected to contribute \$8.5 million in revenue and \$3.1 million in net profit for 2011. To learn more about the new therapeutic products, please visit WKBT’s web site listed in the first paragraph of this report.

## WHY SHOULD YOU CONSIDER WKBT?

***The growing market:*** China’s medical system reform will increase the demand for medicines and health supplements. China also faces the problem of increased elderly population susceptible to disease which also increases the demand for both medical and health supplements. This creates a huge audience that readily accepts the value of herbal medicines and supplements. Few other societies accept a holistic approach to medicine as does China.

With China’s long history and tradition of herbal remedies and nutritional supplementations, it appears to be a perfect match for WKBT.

***Growth Strategy:*** WKBT’s vision consists of a diversified multi-prong approach: Streamline production methods, improved sales, and distribution channel merger and acquisition.

The Company plans to increase advertising of high-margin products and build their brand. WKBT will pursue acquisition targets in the future to diversify its product offerings and distribution channel.

China is the 8<sup>th</sup> largest pharmaceutical market in the world and is forecast to become the 5<sup>th</sup> largest in 2010 and the largest by 2050. (IMS Health, Fredonia Group)

We feel that if the Company continues to expand their products and they continue to follow their business plan, and with their recent announcement of \$0.75 in earnings for 2010, and at 8 x earnings, our intermediate target price of \$6.05 could be obtained.

